30 results about "Chlamydia trachomatis infection" patented technology

Methods and compositions for the treatment or prevention of ocular Chlamydia trachomatis infection. Compositions comprise one or more Chlamydia trachomatis proteins, immunogenic fragments thereof or polynucleotides encoding such proteins or fragments.

The invention provides a kit for detecting chlamydia trachomatis (CT). The kit comprises a nucleic acid releaser and a PCR (Polymerase Chain Reaction) solution, wherein the nucleic acid releaser comprises 0.01-0.5mM/L of surfactin, 20-300mM/L of potassium chloride, 0.01-2% of sodium dodecyl sulfate and 0.05-1% of ethanol; and the PCR solution comprises a forward primer and a reverse primer which are used for amplifying targeted polynucleotide, and a probe for detecting the targeted polynucleotide. A method of releasing nucleic acid by using the nucleic acid releaser in the kit provided by the invention is not obviously different from a boiling method in the detection result, and a violent protein denaturant adopted for the nucleic acid extraction in the method provided by the invention quickly breaks a coat protein structure of a pathogen to release pathogen nucleic acid, so the release and extraction of DNA (Deoxyribonucleic Acid) can be realized without heating; besides, the sensitivity of the provided kit for detecting the CT can be 400 copies/ml, the linearity region of the detection is 400-4.00E+10 copies/ml; and moreover, CT-DNA in an unknown sample such as genital secretions can be quickly and precisely detected by using the kit, so a reliable experiment basis is provided for diagnosing CT infection.

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. trachomatis. The method employs a vector containing a nucleotide sequence encoding a polypeptide of a strain of Chlamydia operably linked to a promoter to effect expression of the gene product in the host. The polypeptides are derived from the Chalmydia gene 60kCRMP gene including truncated forms of the gene. The invention further provides recombinant 60kCRMP protein useful for protecting against disease caused by infection with Chlamydia.

The invention aims at providing a kit which is suitable for rapid test of chlamydia trachomatis in clinical samples and can be used for auxiliary diagnosis and efficacy monitoring of chlamydia trachomatis infection. The technical scheme of the invention is as follows: an PCR (polymerase chain reaction) fluorescence quantitative rapid test kit of the chlamydia trachomatis is provided and comprisesa PCR reaction solution, wherein the PCR reaction solution contains primers and a fluorescence probe; and the primers comprise an upstream primer and a downstream primer, and the kit further comprises a DNA (deoxyribonucleic acid) polymerase, a strong positive quality control product, a weak positive quality control product, a negative quality control product, a positive quantitative reference product and a DNA extraction solution. According to the CT (chlamydia trachomatis) fluorescence PCR quantitative test kit and method provided by the invention, a Taqman core technology platform and an arabidopsis internal reference system are utilized, thus the test sensitivity is higher. Furthermore, the accuracy, specificity, repeatability, stability, sensitivity and precision are improved compared with those of the existing product.

The invention discloses a fluorescent polymerase chain reaction (PCR) kit for detecting chlamydia trachomatis infection by an SYBR Green method and belongs to the field of in-vitro nucleic acid diagnosis kits. The kit comprises a negative reference and control substance, a negative reference substance, fluorescent PCR reaction liquid, Taq enzyme and deoxyribonucleic acid (DNA) extraction liquid. The kit comprises a PCR reaction system in which a fluorescent PCR technology is taken as basis, forward and reverse primers and fluorescent dye SYBR Green aiming at the specific sequence of chlamydia trachomatis, can detect chlamydia trachomatis infection in a clinical sample conveniently and quickly, and has high specificity and great clinical value for early detection of the chlamydia trachomatis.

The invention relates to a recombined chlamydia trachomatis protein and also relates to application of the recombined chlamydia trachomatis protein in preparation of detection kits. The diagnosis kit prepared by using the recombined chlamydia trachomatis protein has advantages of strong specificity, high sensitivity, and simple operation and better meets the requirement of clinical diagnosis of chlamydia trachomatis infection.

The invention relates to test paper for detecting chlamydia trachomatis infection, and the test paper comprises a baseplate, a sample pad, a conjugate pad, a nitrocellulose membrane and an absorption pad, wherein a detection line and a quality control line are arranged on the nitrocellulose membrane, the detection line on the nitrocellulose membrane is coated by mouse anti-human monoclonal protein antibody IgG (antibody II) of major outer membrane protein antigen of chlamydia trachomatis in the concentration of greater than or equal to 1mg/mL, and the quality control line is coated by goat anti-mouse IgG polyclonal antibody in the concentration of greater than or equal to 1.5mg/mL; the conjugate pad is coated by mouse anti-human monoclonal protein antibody IgG (antibody I) of the MOMP (major outer membrane protein) antigen of the chlamydia trachomatis, which is labeled by nano-gold and is in the concentration of not less than 6 mu g/mL; the sensitivity of detecting the MOMP of the chlamydia trachomatis of the test paper is 0.1ng/ml, the detection value range is 0-200ng/ml and the specificity is 98.5%; and the detection can be completed within 5 minutes.

A plasmid isolated from Clamydia trachomatis is described, which comprises 8 genes encoding proteins useful in the formulation of vaccines or diagnostic test for determining the bacterium or specific antibodies generated during C. trachomatis infections; in particular the recombinant fusion MS2-pgp3D protein is described comprising polypeptidic sequences encoded by pCT and immunogenic in the course of infections in man. A method for preparing said protein in E. coli further described.

The invention provides a chlamydia trachomatis recombinant protein and a preparation method thereof, relating to the field of gene engineering technology and diagnostic reagent and vaccine development. The invention relates to a chlamydia trachomatis fusion protein which can be applied to the clinical diagnosis of chlamydia trachomatis infection; and a nucleotide sequence coding the protein comprises plasmids of the nucleotide sequence and pronucleus host cells. The invention also relates to a method for preparing the protein and application thereof. The recombinant protein has high specificity and strong immunogenicity, and can improve the sensitivity and specificity of a detection reagent; and compared with the same kind of kits on the market, the recombinant protein has the advantages of strong specificity, high sensitivity and the like, and perfectly meets the needs in the clinical diagnosis of human chlamydia trachomatis infection.

The invention relates to a Nutritional digestive juice for chlamydia neutralization, in particular to a prescription of a cell culture medium used when a urethritis patient needs the examination of the chlamydia cell culture after using a large amount of clinical antibiotics and a preparation method of the cell culture medium. The genital tract chlamydia trachomatis infection is one of the most common diseases which are sexually transmitted. Chlamydia trachomatis is also regarded as the important cause of the pelvic inflammatory disease and the sequelae (tubal infertility and ectopic pregnancy) thereof. The chlamydia cell culture method is the most sensitive and the most reliable method used for examining the chlamydia. The culture medium can detect out the positive result of the genital tract chlamydia after the large amount of clinical antibiotics is used, thereby having the function of the clinical diagnosis guidance and the clinical treatment and the important meaning of preventing the abuse of the antibacterial drugs.

The invention belongs to the field of in-vitro nucleic acid detection and aims to provide a rapid detection kit applicable to Chlamydia trachomatis in a clinical sample and used for assisted diagnosis of Chlamydia trachomatis. A rapid fluorescence PCR detection kit for Chlamydia trachomatis comprises a PCR liquid, a negative quality control material, a positive quality control material, a weak positive quality control material, lysate and proteinase K, wherein the PCR liquid contains TaqDNA polymase for hot starting, forward and reverse primers and SYBRGreenI pigment, and the forward and reverse primers are specific primers designed for specific sequence of Chlamydia trachomatis and are capable of specifically amplifying a target DNA sequence, so that the clinical diagnosis purpose is achieved. The kit disclosed by the invention can be used for simply and rapidly detecting the infection of Chlamydia trachomatis in the clinical sample and has the characteristics of high specificity and high sensitivity.

The invention provides an RNA (Ribonucleic Acid) target SAT (Simultaneous Amplification and Testing) based molecular biological detection method for ureaplasma urealyticum infection. The method comprises the following steps: I, by using a specific target capturing technique, extracting pure cell target nucleic acid by using a magnetic bead method, that is, taking RNA as a target, namely (1-1) manually extracting target nucleic acid specificity, and (1-2) extracting pure cell target nucleic acid, that is, taking RNA as the target; II, obtaining detection results of chlamydia trachomatis infection by using an RNA real-time fluorescent constant-temperature amplification detection technique, namely (2-1) generating one DNA (Deoxyribonucleic Acid) copy of the target nucleic acid RNA through M-MLV reverse transcriptase, (2-2) generating multiple RNA copies from the DNA copy by using T7RNA polymerase, and (2-3) specifically combining an optimized probe with a fluorescent marker and the extracted RNA copies so as to generate a fluorescent signal which is captured by using a detector, and obtaining a detection result of chlamydia trachomatis infection according to signal appearance time andintensity; III, with the combination of a positive reference and a negative reference, judging detection results, and carrying out bacterium testing.

The present invention provides nucleic acids, proteins and vectors for a method of nucleic acid, including DNA, immunization of a host, including humans, against disease caused by infection by a strain of Chlamydia, specifically C. trachomatis. The method employs a vector containing a nucleotide sequence encoding a Mgp002 polypeptide of a strain of Chlamydia operably linked to a promoter to effect expression of the gene product in the host. Truncated forms of the full-length Mgp002 gene are useful immunogens for protecting against disease caused by infection with Chlamydia. The invention further provides recombinant Mgp002 protein useful for protecting against disease caused by infection with Chlamydia.

The invention discloses an application of small molecule inhibitors VX-11e and BVD-523 in inhibiting chlamydia infection. The research found that the signal pathway inhibitors VX-11e and BVD-523 can obviously inhibit the infection of the chlamydia trachomatis, and have significant difference compared with the reported MEK inhibitor U0126; according to the application of small molecule inhibitors VX-11e and BVD-523 in inhibiting chlamydia infection, the small molecule inhibitors VX-11e and BVD-523 are applied to chlamydia infection for the first time, and are expected to be new drugs for chlamydia targeting host therapy; the research also found that inhibitors VX-11e and BVD-523 had synergistic effect with azithromycin. After chlamydia infection, VX-11e and BVD-523 could promote the anti-infection effect of azithromycin, which was of great value in the treatment of chlamydia infection. The application of small molecule inhibitors VX-11e and BVD-523 in inhibiting chlamydia infection hasimportant significance for the development of new drugs for chlamydia trachomatis infection and the search of new targets for auxiliary host therapy.

The invention provides a molecular-biological detection method for chlamydia trachomatis infection based on SAT (Simultaneous Amplification and Testing) of a RNA target. The molecular-biological detection method comprises the following steps: step (1) adopting a specific target capture technology and a magnetic-bead method to extract pure cell target nucleic acid, i.e., adopting RNA as the target,wherein comprising (1-1) the specificity of the target nucleic acid is manually extracted; (1-2) the pure cell target nucleic acid is obtained, i.e., RNA is used as a target; step (2) adopting a RNAreal-time fluorescent constant-temperature amplification detection technology to obtain a detection result for chlamydia trachomatis infection, wherein comprising (2-1) M-MLV reverse transcriptase generates a DNA copy of the target nucleic acid; (2-2) T7RNA polymerase generates multiple RNA copies from the DNA copy; (2-3) an optimizing probe with fluorescence labeling is specifically combined withthe extracted RNA copy, so that a fluorescence signal generated is captured by a detection instrument, and the detection result for the chlamydia trachomatis infection is obtained according to the occurring time and the intensity of the signal; step (3) judging the detection result by combination with positive control and negative control.

The invention discloses an application of RSK signal channel inhibitors to restraining chlamydia trachomatis infection. Through research, the inventor finds that RSK signal channel inhibitors LJH685 and LJI308 can restrain chlamydia trachomatis infection and are effective on the chlamydia trachomatis of different cell types and different serotypes, and the RSK signal channel inhibitors are appliedto the chlamydia trachomatis infection for the first time, and hopefully become new medicines for chlamydia trachomatis targeted host treatment. Besides, through research, the inventor also finds that when the RSK signal channel inhibitors LJH685 and LJI308 and azithromycin are in united application, synergistic effects can be achieved, after the chlamydia trachomatis infection, the LJH685 and the LJI308 can promote the anti-infection effect of the azithromycin, and the RSK signal channel inhibitors have important application value on treating the chlamydia trachomatis infection. The RSK signal channel inhibitors have important significance on developing the new medicines for the chlamydia trachomatis infection and seeking new target points for auxiliary host treatment.